UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/722,086	11/24/2003	Charles B. Chapman	100201800-1	7958	
	22879 7590 03/18/2008 HEWLETT PACKARD COMPANY			EXAMINER	
P O BOX 272400, 3404 E. HARMONY ROAD INTELLECTUAL PROPERTY ADMINISTRATION			BOWERS, NATHAN ANDREW		
	S, CO 80527-2400		ART UNIT	PAPER NUMBER	
			1797		
			NOTIFICATION DATE	DELIVERY MODE	
			03/18/2008	ELECTRONIC	

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

JERRY.SHORMA@HP.COM mkraft@hp.com ipa.mail@hp.com

	Application No.	Applicant(s)	
	10/722,086	CHAPMAN, CHARLES B.	
Office Action Summary	Examiner	Art Unit	
	NATHAN A. BOWERS	1797	
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with the	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period.  - Failure to reply within the set or extended period for reply will, by stat Any reply received by the Office later than three months after the ma earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be downward will expire SIX (6) MONTHS froute, cause the application to become ABANDON	DN.  timely filed  m the mailing date of this communication.  IED (35 U.S.C. § 133).	
Status			
Responsive to communication(s) filed on 15     This action is <b>FINAL</b> . 2b) ☐ TH     Since this application is in condition for allow closed in accordance with the practice unde	nis action is non-final. vance except for formal matters, p		
Disposition of Claims			
4)  Claim(s) 1,4-12 and 15-35 is/are pending in 4a) Of the above claim(s) 15-35 is/are withdr 5)  Claim(s) is/are allowed. 6)  Claim(s) 1 and 4-12 is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) are subject to restriction and	rawn from consideration.		
Application Papers			
9) The specification is objected to by the Exami 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the	ccepted or b) objected to by the ne drawing(s) be held in abeyance. S ection is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a li	ents have been received. ents have been received in Applica riority documents have been receive eau (PCT Rule 17.2(a)).	ntion No ved in this National Stage	
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4) Interview Summa Paper No(s)/Mail 5) Notice of Informal 6) Other:		

#### **DETAILED ACTION**

### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

1) Claims 1 and 4-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wilding (US 20030199081) in view of Mowry (US 7078237) and/or Doung (US 20020177135).

Application/Control Number: 10/722,086

Page 3

Art Unit: 1797

With respect to claims 1 and 5-12, Wilding discloses a disposable biochip comprising a substrate and a region on the substrate having components configured to interact with a biological substance. More specifically, Wilding discloses a PCR chamber (Figure 1:22) within which nucleic acid samples interact with reagents required for amplification. This is described in paragraph [0040] and [0044]. Paragraphs [0014] and [0045] indicate that the temperature of the PCR chamber is regulated by microprocessor controlled resistance heaters positioned in the substrate. These resistance heaters are configured to assist the reagent components in interacting with the nucleic acid samples. According to the protocol of PCR, the heaters move the temperature of the biochip through at least one heating cycle to amplify the DNA. Paragraph [0052] additionally states that the microprocessor acts as a bio-analysis device capable of detecting and recording data obtained during an assay. Wilding, however, does not state that the heating devices are configured to generate heat sufficient to pyrolyze the nucleic acid sample following normal thermalcycling procedures.

Mowry discloses a biochip that comprises a substrate (Figure 1:120) and a heating device (Figure 1:110) integrated with the substrate in order to form a pyrolysis stage (Figure 2:100). This is described in column 4, lines 8-30. Column 6, lines 30-47 indicate that the heating device is configured to generate heat sufficient to pyrolyze a biological substance disposed within the biochip.

Doung discloses a disposable biochip capable of performing PCR and facilitating the detection of nucleic acid analytes through the use of hybridization arrays. Doung indicates that a plurality of heating means and thermocontrollers are utilized to regulate the temperature within reaction chambers during amplification and detection processes. In paragraph [0326], Doung

teaches that it is known in the art to use heating means disposed upon a biochip to create extreme temperatures over a sufficient period of time sufficient to kill and destroy a biological sample.

Wilding, Mowry and Doung are analogous art because they are from the same field of endeavor regarding biochips.

At the time of the invention, it would have been obvious to utilize the heating means disclosed by Wilding to generate extreme temperatures in order to pyrolyze biological substances following normal thermalcycling procedures. Mowry indicates in column 4, lines 8-30 that resistive heating elements, similar to those disclosed by Wilding, are capable of producing temperatures sufficient to pyrolyze a variety of biochemical compounds. Doung teaches in paragraph [0326] that it is beneficial to destroy biological samples via heat treatment after analysis because many samples are dangerous and would pose health problems to operators if contacted.

With respect to claim 4, Wilding and Mowry/Doung disclose the apparatus set forth in claim 1 as set forth in the 35 U.S.C. 103 rejection above. Wilding additionally indicates in paragraphs [0051]-[0057] that the heating device is in communication with a variety of bioanalysis devices capable of detecting the PCR product.

## Response to Arguments

Applicant's arguments filed 15 January 2008 with respect to the 35 U.S.C. 103 rejections involving the combination of Wilding with Mowry and/or Doung have been fully considered but they are not persuasive.

Applicant's principle arguments are

(a) Wilding does not disclose that the heat generated by the heating device produces a temperature sufficient to destroy biological substances. This deficiency is not addressed by Mowry and Doung. Mowry discloses teaches that the micropyrolyzer does not destroy samples, but rather serves the purpose of vaporizing samples for analysis. The thermal controller in Doung, while capable of destroying samples, is not a part of a biochip.

In response to Applicant's arguments, please consider the following comments.

Wilding discloses every structural feature set forth in the independent claims. Wilding clearly teaches (1) a disposable substrate, (2) a region of the substrate having components configured to interact with a biological substance, (3) a heating device, and (4) a bio-analysis device. Wilding teaches that the purpose of the heating device is to conduct PCR, and Wilding is silent as to whether or not the heating device is used to decontaminate the biochip. It is not suggested that one of ordinary skill in the art, after reviewing the teachings of Mowry and Doung, would add extra features to the apparatus of Wilding. It is not suggested that one would be motivated to put the chip of Wilding within an external heating block (as disclosed by Doung) because the chip of Wilding already comprises a plurality of programmable heating elements integrally attached to the chip substrate.

Instead, one of ordinary skill in the art would be motivated to use the existing features disclosed by Wilding in new ways to achieve additional benefits. More specifically, a skilled practitioner would find it obvious to use the heater disclosed by Wilding to pyrolyze biological substances within the chip once the PCR assay is completed. It is beneficial to destroy biological samples via heat treatment after analysis because many samples are dangerous and would pose health problems to operators if contacted.

There is no reason to believe that the existing heaters disclosed by Wilding are incapable of destroying a biological sample in order to ready the chip for disposal upon completion of the experiment. The electrical resistance heating elements disclosed by Wilding are very similar, if not identical, to the heating elements disclosed by Mowry and Doung.

### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/722,086 Page 7

Art Unit: 1797

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nathan A. Bowers whose telephone number is (571) 272-8613.

The examiner can normally be reached on Monday-Friday 8 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gladys Corcoran can be reached on (571) 272-1214. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/William H. Beisner/ Primary Examiner, Art Unit 1797

/Nathan A Bowers/ Examiner, Art Unit 1797